The authors examined SEER-Medicare records from 78,552 patients undergoing ADT, and found 43% reporting higher 3-year cumulative incidence of anxiety (4.1% vs. 3.3%). Propensity matching analysis showed 17% increase in the level of anxiety for patients on ADT. The risk of anxiety increased with duration of therapy, peaking at 15.7% in those treated for ≥12 mo. In addition, the result was consistent in subgroups according to race, prostate cancer risk group, Charleson comorbidity index, and treatment modality.
This is the first study examining the role of anxiety in patients placed on androgen deprivation therapy. As the longevity of metastatic prostate cancer patients increases, their quality of life certainly deserves attention. As this study clearly illustrates, androgen deprivation is not without its own perils.
First Author: Kathryn Dinh
at the 2017 Genitourinary Cancers Symposium - February 16 - 18, 2017 – Orlando, Florida USA